Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage I prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 58 for your search:
Start Over
Surgery with or without Docetaxel and Leuprolide Acetate or Goserelin Acetate in Treating Patients with High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 90203, NCI-2009-00496, CDR0000526353, NCT00430183
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-497, NCI-2012-01144, NCT01617161
A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR102931, NCI-2013-02187, 2012-004322-24, ARN-509-003, NCT01946204
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Magnetic Resonance Spectroscopic Imaging in Finding Tumors in Patients with Stage I-III Prostate Cancer Planning to Undergo Prostate Surgery
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 2006-0516, NCI-2011-00517, PC061612, NCT00464724
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 50 to 80
Trial IDs: MTG-REIC-PC003, NCI-2014-01003, NCT01931046
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Stereotactic Body Radiation Therapy with Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: UW14083, NCI-2015-00950, 2015-0395, NCT02470897
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
Hypofractionated Image-Guided Radiation Therapy In Treating Patients with Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J0859, NCI-2010-02069, NA_00019393, NA_00019393 / CIR00008106, NCT00809991
Hypofractionated Stereotactic Body Radiation Therapy in Patients With Low- or Intermediate-Risk Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-031, NCI-2011-02495, NCT00977860
Prostatic Acid Phosphatase-Sargramostim Fusion Protein or Sargramostim in Treating Patients with Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO 08801, NCI-2011-00965, H-2008-0073, NCT01341652
Metformin Hydrochloride and Simvastatin in Treating Patients With Recurrent Prostate Cancer After Surgery and/or Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: H-28936, NCI-2013-01344, H-28989, NCT01561482
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, UCSF CC# 115516, NCT01695473
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 and over
Trial IDs: Pro00041857, NCI-2013-00581, 00041857, Amd020_Pro00041857, NCT01763944
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 125513, NCI-2013-02375, CC#125513, NCT01787331
Docetaxel and Lycopene in Treating Patients with Hormone-Resistant Prostate Cancer Not Previously Treated with Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: UCI 10-11, NCI-2011-00037, 2010-7765, NCT01882985
Start Over